Skip to main content
. Author manuscript; available in PMC: 2012 Dec 15.
Published in final edited form as: Cancer. 2011 Jun 3;117(24):5548–5559. doi: 10.1002/cncr.26216

Table 3.

Early treatment response as determined by gadolinium-enhanced MRI 1 month post treatment and 6-month PFS and median overall survival

All patients Metastatic Disease CNS Primary
Partial Response 2 (15%) 2 (20%) 0 (0%)
Stable Disease 9 (70%) 6 (60%) 3 (100%)
Progressive Disease 2 (15%) 2 (20%) 0 (0%)
6-month PFS 9 (60%) 8 (67%) 1 (33%)
Median OS 8.8 months 7.6 months Not reached